Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;63(1):96-99.
doi: 10.1002/mus.27016. Epub 2020 Aug 3.

A neuromuscular-based analysis of the open payments program

Yohei Harada  1 , Sen Sheng  1 , Vaishali A Thombre  2 , Songthip Ounpraseuth  2 , Carolina Gil Tommee  1 , Amarnath R Annapureddy  3 , Mudassar Kamran  4 , Madhu S Jasti  5 , Masahisa Katsuno  6 , Sisira Yadala  1 , Karthika Veerapaneni  1 , Nidhi Kapoor  1 , Sukanthi Kovvuru  1 , Sanjeeva Reddy Onteddu  1 , Krishna Nalleballe  1
Affiliations

A neuromuscular-based analysis of the open payments program

Yohei Harada et al. Muscle Nerve. 2021 Jan.

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Muscle Nerve. 2021 Sep;64(3):E17. doi: 10.1002/mus.27357. Epub 2021 Jul 23. Muscle Nerve. 2021. PMID: 34297848 No abstract available.

Abstract

Introduction: In August 2013, the Centers for Medicare and Medicaid Services (CMS) Open Payments Program (OPP) made eligible payment information publicly available. Data about industry payments to neuromuscular neurologists are lacking.

Method: Financial relationships were investigated between industry and US neuromuscular neurologists from January 2014 through December 2018 using the CMS OPP database.

Results: The total annual payments increased more than 6-fold during the study period. The top 10% of physician-beneficiaries collected 80% to 90% of total industry payments except in 2014. In 2018, the most common drugs associated with payments to neuromuscular neurologists were nusinersen, vortioxetine, eteplirsen, alglucosidase alpha, edaravone, and intravenous immunoglobulin.

Discussion: A substantial increase in the annual payments to neuromuscular physicians during the study period is likely due to the development of new treatments, including gene therapy.

Keywords: clinical; health economics; neuromuscular; neuromuscular disorder; open payment.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician-industry relationships. N Engl J Med. 2007;356:1742-1750.
    1. Bero L. Industry sponsorship and research outcome: a Cochrane review. JAMA Intern Med. 2013;173:580-581.
    1. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006;295:429-433.
    1. ABIM Foundation. American Board of Internal MedicineMedical professionalism in the new millennium: a physician charter. Ann Intern Med. 2002;136:243-246.
    1. Agrawal S, Brennan N, Budetti P. The sunshine act-effects on physicians. N Engl J Med. 2013;368:2054-2057.

LinkOut - more resources